GenScript and InnoBation Enter into the Agreement for CAR-T therapy

GenScript and InnoBation Enter into the Agreement for CAR-T therapy

NANJING, China and SEOUL, South Korea, Dec. 15, 2020 /PRNewswire/ — A global leading biotech company GenScript Biotech Corporation (“GenScript”, Stock Code: 1548.HK) announces that it has reached the agreement for cell line development and engineering, manufacture service of GMP Plasmids and Lentivirus with InnoBation Co., Ltd. a company that specializes in developing biomarkers and CAR-T cell treatment products.

GenScript and InnoBation Enter into the Agreement for CAR-T therapy
GenScript and InnoBation Enter into the Agreement for CAR-T therapy

InnoBation is a Republic of Korea based Biotech Company, currently working closely with the Korean National Cancer Center on the ‘IBC 101’ project, a bi-specific CAR-T therapy product, and several other CAR-T projects for hematological malignancies and solid tumors.

Through this agreement, GenScript will provide CRO services for developing engineered cell line using CRISPR CAS 9 technology and GenScript ProBio, the CDMO division of GenScript, will offer high-quality one-stop platform services of developing and manufacturing plasmid and lentivirus for preclinical and clinical trials, which would be required for InnoBation’s CAR-T therapy development.

“We are delighted to reach the collaboration with InnoBation in the field of CAR-T therapy. In recent years, the Republic of Korea has sprouted many innovative biotech companies, and InnoBation is one of leading innovative technology companies with the latest technology for immunotherapy.” Yuyu Hu, Business development Head of GenScript Korea said, “We look forward to applying our superior process development capabilities together with InnoBation’s insight into immunotherapeutic drug discovery and development to truly forge new frontiers in bringing personalized immunotherapies to patients.”

About InnoBation, Co., Ltd.

InnoBation Co., Ltd., headquartered in the Republic of Korea is a biotechnology company, having established two major platforms. First, its R&D activities focus on developing liquid biopsy-based biomarkers for screening cancer patients and for companion diagnostic of immune-checkpoint inhibitors. To date, several biomarkers have been placed on clinical trials. Second, it has developed CAR (chimeric antigen receptor)- T cell therapies for solid tumors and hematological malignancies. CAR-T pipelines would be further developed with partners, moving it to the clinical trial.

About GenScript Biotech Corporation

GenScript Biotech Corporation (Stock Code: 1548.HK) is a global biotechnology group. Based on its leading gene synthesis technology, GenScript has developed four major platforms including the global cell therapy platform, the biologics contract development and manufacturing organization (CDMO) platform, the contract research organization (CRO) platform and the industrial synthesis product platform. GenScript’s business operation spans over 100 countries and regions worldwide with legal entities located in the US, Mainland China, Hong Kong, Japan, Singapore, Netherlands and Ireland.

GenScript ProBio, the CDMO division of GenScript, is providing solutions for antibody drug discovery, biologics development, and gene and cell therapy, dedicated to providing end-to-end service from discovery to commercialization with proactive strategies, professional solutions and efficient processes to accelerate the commercialization of medicines, and building a healthier future.

For more information visit www.genscript.com.